TY - JOUR T1 - Combination Therapy with VP16 and Ethinylestradiol for Hormone-Refractory Prostate Cancer: Good Response with Tolerability JF - Anticancer Research JO - Anticancer Res SP - 3737 LP - 3745 VL - 30 IS - 9 AU - HARUHITO AZUMA AU - TERUO INAMOTO AU - KIYOSHI TAKAHARA AU - NAOKAZU IBUKI AU - KOHEI KOYAMA AU - SYNYA UTIMOTO AU - YUTAKA FUJISUE AU - HIROHUMI UEHARA AU - KAZUMASA KOMURA AU - HAYAHITO NOMI AU - TAKANOBU UBAI AU - YOJI KATSUOKA Y1 - 2010/09/01 UR - http://ar.iiarjournals.org/content/30/9/3737.abstract N2 - Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70% of patients showed a >50% reduction (complete response [CR] 51%, partial response 23%) and >90% showed a clinical response. Of 58 patients with measurable lesions, 24% (14/58) showed a CR, and most of these patients (13/14, 93%) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC. ER -